In this study, we describe a competitive homogeneous immunoassay that makes use of Förster resonance energy transfer (FRET) in rapid detection of pathogen-specific antibodies. The assay principle is based on competition between a monoclonal antibody (MAb) and serum antibodies to a given antigen. In the assay, named competitive FRET immunoassay (CFRET-IA), the FRET signal is induced if MAb carrying a donor label binds to an acceptor-labeled antigen. Specific antibodies in serum compete for antigen binding, resulting in reduced FRET signal. The proof-of-principle for the assay was obtained using donor-labeled Puumala virus nucleocapsid protein (PUUV-N) and acceptor-labeled anti-PUUV-N MAb. The assay was evaluated by analyzing 329 clinical samples comprising 101 from individuals with acute PUUV infection, 42 from individuals with past infection, and 186 from individuals with PUUV-seronegative sera, and the results were compared to those of reference tests. The rapid serodiagnostic test we introduced herein performed with 100% sensitivity and 99% specificity for diagnosing acute hantavirus disease.
H
antaviruses (family Bunyaviridae), some of which are zoonotic, are carried by chronically infected rodents and insectivores. Transmission to humans typically occurs via inhalation of aerosolized virus-contaminated excreta (feces, saliva, and urine) of the reservoir rodent host. The clinical manifestations of hantavirus infections vary, and they comprise two disease entities: hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). The pathogenic hantaviruses in Europe cause HFRS, whereas some of the hantaviruses circulating in the Americas cause HCPS.
The most common hantavirus circulating in Europe is Puumala virus (PUUV), carried by bank voles (Myodes glareolus), and it is the causative agent of nephropathia epidemica (NE), a mild form of HFRS. Annually, ϳ50,000 HFRS cases occur in Eurasia, while in the Americas a grand total of ϳ3,500 HCPS cases have been recorded since their identification in 1993 (1) . Typical symptoms of NE include abrupt fever, followed by headache and nausea, vomiting, abdominal pain, and signs of renal insufficiency. Pulmonary, cardiac, and central nervous system symptoms, as well as somnolence and visual disturbances, are also common (2) (3) (4) (5) . Laboratory diagnosis of PUUV infection is based on the detection of immunoglobulin M (IgM) to PUUV or low avidity of immunoglobulin G (IgG). Both IgM and IgG specific to the nucleocapsid protein (N) are produced early in infection. The antibody detection is commonly based on enzyme immunoassay (EIA), immunoblotting using recombinant PUUV N as antigen, or immunofluorescence assay (IFA) based on acetone-fixed infected cells. Additionally, rapid immunochromatography tests for IgM detection are available (6) (7) (8) .
In this report, we introduce a novel rapid serodiagnostic test for acute PUUV infection utilizing Förster resonance energy transfer (FRET). A wide variety of research fields have utilized FRET for proximity-based assays (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . FRET is a phenomenon in which two fluorophores, the first one acting as a donor and the other as an acceptor, transfer energy from one to the other (donor to acceptor) if in close proximity (Ͻ10 nm). We have recently applied time-resolved FRET (TR-FRET) for antibody detection in homogeneous immunoassays based on two different principles (15, 16, 18) . The FRET bridge approach (15) employs energy transfer between donor-labeled and acceptor-labeled antigens brought in proximity by immunoglobulins. The LFRET approach (16, 18) relies on a TR-FRET signal induced by the simultaneous binding of an acceptor-labeled immunoglobulin-binding protein L and a donor-labeled antigen to the Fab arm of an immunoglobulin. The rapid homogeneous immunoassay we describe herein, the competitive FRET immunoassay (CFRET-IA), is based on competition between a fluorophore-labeled monoclonal antibody (MAb) and serum antibodies. The MAb (anti-PUUV-N) is labeled with the donor fluorophore (europium), and the antigen (PUUV-N) is labeled with the acceptor fluorophore (Alexa Fluor 647). The presence of antibodies (IgG or IgM) against PUUV-N in serum is detected via a decrease in the TR-FRET signal.
MATERIALS AND METHODS
Clinical samples and ethical statement. We studied two separate panels consisting of 128 archival (Ϫ20°C) serum samples (panel 1) and 201 freshly collected serum samples (panel 2). All of these samples had been sent to Helsinki University Hospital Laboratory (HUSLAB, Department of Virology and Immunology, Zoonosis Unit) during 2010 to 2015 for analysis of PUUV IgM and IgG due to suspicion of acute PUUV infection. The serum samples were reexamined under HUSLAB's research permission (granted by the ethics committee on 14 June 2013).
Proteins and antibodies. Baculovirus-expressed PUUV N (19) was purchased from Reagena Ltd. and was labeled with europium (Eu) using the QuickAIIAssay Eu chelate protein labeling kit (BN Products & Services Ab Oy) as instructed by the manufacturer. The bank vole anti-PUUV antibodies (MAb 3H9 and MAb 1C12) have been described previously (20) and were purified from hybridoma cell culture supernatants and labeled with AF647 according to the manufacturer's instructions. IgG-free bovine serum albumin (BSA) was obtained from Jackson ImmunoResearch, Inc.
TR-FRET assays. Two dilutions of each serum sample were prepared: one with IgG depletion and one without. The IgG depletion was performed as described previously (18) , and a 1/50 dilution (on the plate) was used for further analyses. The sample without IgG depletion was directly diluted 1/50 (on the plate). The TR-FRET assay protocol was, briefly, as follows. After dilution of the reaction components in Tris-buffered saline supplemented with BSA (TBS-BSA; 50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.2% BSA), 10 l of the antigen solution and 5 l of the serum dilution were combined and dispensed on a 384-well microplate (ProxiPlate-384 Plus F, Black 384, shallow-well microplate [PerkinElmer] ) and incubated at room temperature (RT) for 10 min. Thereafter 5 l of MAb dilution was added to each well, followed by incubation for 15 min at RT. Finally, the results (TR-FRET values) were measured with a Wallac Victor 2 fluorometer (PerkinElmer). The TR-FRET values were normalized by following a protocol described previously (15) . All experiments were performed in duplicate. The assay principle is schematically illustrated in Fig. 1 .
The concentrations of the assay components were optimized with cross-titration (16) using a panel of 58 serum samples. The optimal serum dilution for the assay was determined to be 1/50 (in the plate), and the respective concentrations for the labeled MAb 3H9 and PUUV-N were 2.5 nM and 5 nM. A pool of PUUV-negative sera was used as a negative control in each measurement. The results are presented as relative TR-FRET inhibition [obtained by the following equation: 100 ϫ (x Ϫ y)/x, wherein y is the average of normalized TR-FRET values measured for each sample, and x represents the analogous values measured for the negative control].
Monoclonal antibody comparison. Initially, the performances of the two MAbs (3H9 and 1C12) were compared in parallel experiments, with a panel of 15 serum samples, including five from individuals with acute PUUV infection (IgG ϩ /IgM ϩ ), five from individuals with past PUUV infection (IgG ϩ /IgM Ϫ ), and five from PUUV-seronegative individuals. Reference methods. The reference test results for PUUV IgM (specificity, 100%; sensitivity, 100%) and IgG (specificity, 100%; sensitivity, 96%) antibodies were obtained from HUSLAB (7, 19, (21) (22) (23) . The IgG antibodies were detected by an in-house immunofluorescence assay (IFA) based on PUUV-infected acetone-fixed Vero E6 cells (6, 7, 19) . The IgM antibodies against PUUV-N were detected by -capture IgM EIA based on recombinant PUUV-N produced as for the CFRET-IA (19) . Both of the reference tests are accredited (SFS-EN ISO/IEC 17025 and SFS-EN ISO 15189) and have been in routine use (HUSLAB, Department of Virology and Immunology) for PUUV diagnosis for approximately 20 years. PUUV IFA for IgM was performed like the IFA for IgG except that the serum was preabsorbed (for IgG depletion) with GullSORB as described previously (18) prior to 3 h of incubation for the serum dilutions, using as the secondary antibody fluorescein isothiocyanate (FITC)-conjugated, goat anti-human IgM from Jackson ImmunoResearch at a 1:50 dilution.
Evaluation of assay performance. We first determined the assay performance using a retrospective serum panel (panel 1) of 128 samples, including 61 from individuals with acute PUUV infection (IgG ϩ /IgM ϩ ), 28 from individuals with past PUUV infection (IgG ϩ /IgM Ϫ ), and 39 from PUUV-seronegative individuals. We then studied the assay performance using a prospective panel (panel 2) of 201 coded samples representing acute PUUV infection (IgG ϩ /IgM ϩ ; n ϭ 40), past PUUV infection (IgG ϩ / IgM Ϫ ; n ϭ 14), and seronegatives (n ϭ 147). The results from both panels were compared to those obtained by the reference method. All contradictory results as well as all acute-phase and past-infection samples were examined twice to confirm the results.
In addition, we determined the sensitivity of CFRET-IA by titrating 20 samples, including those from individuals with acute and past infections, in serial dilutions (at 4-fold steps) from 1:50 to 1:12,800. The samples were picked randomly from the acute-infection and past-infection sections of panel 2. The same samples were studied with the reference IgG IFA at dilutions of 1:40 to 1:10,240 (4-fold steps). In addition, the acute-phase samples were also studied with the reference enzyme-linked immunosorbent assay (ELISA) at dilutions of 1:200 to 1:125,000 (5-fold steps), as well as with the IgM IFA at dilutions of 1:40 to 1:10,240 (4-fold steps). Spearman's correlations of titers obtained from CFRET-IA to those obtained from reference tests, and the respective P values, were calculated using the SAS 9.3 program. To compare the performances of CFRET-IA and the protein L-based assay LFRET introduced earlier, we analyzed 124 (60 acute-infection, 26 past-infection, and 45 seronegative) samples as described previously (18) .
RESULTS

Selection of PUUV-N MAbs and setting up of the competitive
FRET inhibition assay parameters. Our aim was to set up a com- petitive TR-FRET inhibition assay for serodiagnosis of PUUV infection using PUUV-N recombinant antigen and PUUV-N-specific MAbs. To this end, we set out to determine the assay parameters and selected the anti-PUUV-N MAb to be used with clinical samples.
We chose a panel of 15 samples representing five individuals with acute PUUV infection (IgG ϩ /IgM ϩ ), five individuals with past PUUV infection (IgG ϩ /IgM Ϫ ), and five PUUV seronegatives and separately tested these samples with two bank vole-derived PUUV-N MAbs: 3H9 (PUUV specific; epitope in nonconserved region, amino acids [aa] 251 to 260 [24] , of PUUV-N) and 1C12 (cross-reactive among several rodent-borne hantaviruses, and the conserved epitope locates to the first 61 N-terminal amino acids of N protein (23, 25) . By measuring TR-FRET, we found that while both of the MAbs were inhibited by sera of PUUV-seropositive individuals, they differed substantially in extent of inhibition (Fig.  2) . MAb 3H9 was inhibited proportionately more than MAb 1C12, both by the acute-phase samples and by most of the pastinfection samples. Therefore, we decided to continue the experiments only with MAb 3H9.
PUUV antibody-competitive FRET inhibition assay performance using retrospective samples-proof of concept. We optimized the CFRET-IA performance using a panel of 61 archival serum samples studied for the presence of PUUV antibodies in a diagnostic laboratory (panel 1). The samples represented acute PUUV infection (IgG ϩ /IgM ϩ ; n ϭ 21), past PUUV infection (IgG ϩ /IgM Ϫ ; n ϭ 19), and seronegatives (IgG Ϫ /IgM Ϫ ; n ϭ 21). We observed that of the acute-phase samples, all (21/21) induced greater than 20% relative TR-FRET inhibition with or without IgG depletion. All seronegative samples induced less than 20% relative TR-FRET inhibition regardless of IgG depletion. Of the past-infection samples, 15/19 induced relative TR-FRET inhibition above 20% without IgG depletion, whereas the inhibition was below 20% in all sera with IgG depletion. Based on the data with sample panel 1 (n ϭ 61), we set the cutoff for positivity at 20% relative TR-FRET inhibition, which corresponds to the mean ϩ 3.6 standard deviations (SDs) of the inhibition values of the negative samples without GullSORB treatment and the mean ϩ 3.8 SDs of the inhibition values of the negative samples with Gull-SORB treatment. By comparing the results obtained with and without IgG depletion, we could distinguish acute PUUV infection (Ͼ20% relative TR-FRET inhibition with or without IgG depletion) from past infection (Ͼ20% only when IgG was present) and seronegativity (Ͻ20% relative TR-FRET inhibition regardless of IgG depletion). Next, we probed the CFRET-IA with the remaining 67 samples of panel 1. The results are summarized in Table 1 .
Prospective analysis of clinical samples. After defining the CFRET-IA parameters, we used it prospectively on a panel of 201 blind-coded samples (from the daily series of HUSLAB), in the absence of freeze-thawing. Before IgG depletion, 40/40 acute-infection samples and 12/14 past-infection samples were identified as positive (Ͼ20% relative inhibition, values ranging between 30 and 50%). After IgG depletion, all of the acute-infection samples remained positive, whereas all the past-infection samples became negative (Ͻ20% relative inhibition). Two (2/147) negative samples gave a false-positive result; according to the criteria given, one was identified as an acute-infection sample and the other as a past-infection sample ( Table 2 ). The mean and standard deviation for all studied seronegative samples were 4% and 5.6%, respectively. The results for sample panels 1 and 2 are summarized in Table 3 .
Comparison of antibody titers. We compared the sensitivity and detection limits of the CFRET-IA to those of the reference tests by analyzing dilution series of PUUV antibody-positive samples by the two methods. We titrated 20 randomly chosen PUUV antibody-positive samples (10 acute-phase samples and 10 pastinfection samples) in all assays (CFRET-IA, IgG IFA, IgM ELISA, and IgM IFA). The highest IgM titer detected by CFRET-IA was 3,200, whereas for ELISA it was 125,000, and for IgM IFA it was 2,560. In turn, the highest IgG titer detected by CFRET-IA was 200, whereas for IgG-IFA it was 3,200 (Table 4) . While a comparison of the IgG or IgM titers of the selected 20 sera to the CFRET-IA titers yielded generally poor correlation, a significant correlation (Spearman's correlation coefficient [r] ϭ 0.62; P ϭ 0.0036) was observed when a comparison was done of the sum of Acute  61  61  1  0  0  0  Past  0  0  21  28  0  0  Negative  0  0  6  0  39  39   Total  61  61  28  28  39  39 a A retrospective sample panel was used to set up assay parameters. The sample panel included 61 acute-phase samples (acute), 28 past-infection samples (past), and 39 negative samples. The threshold for positivity in CFRET-IA was set at Ͼ20% relative TR-FRET inhibition.
the IgG and IgM titers of these samples in IFA (in 2-logarithmic scale) with the CFRET-IA titer. We also compared the performances of CFRET-IA and the protein L-based assay LFRET (18) by analyses with both assays of 124 (60 acute-infection, 26 pastinfection, and 45 seronegative) samples. None of the seronegative samples tested positive in either assay. While a positive reaction with CFRET-IA was obtained in 100% of acute-infection samples and in 73% of past-infection samples, the corresponding values with LFRET were 95% and 54%.
DISCUSSION
We introduce a novel homogeneous (i.e., wash-free) rapid competitive immunoassay for human infectious disease diagnostics. The assay, referred to as CFRET-IA, is based on competition between a fluorophore-labeled MAb and serum antibodies. A similar approach has been described for detection of anti-Brucella antibodies in ruminant serum samples (26) . McGiven et al. had labeled anti-Brucella MAb with the donor fluorophore terbium chelate (Tb) and a Brucella antigen with the acceptor fluorophore fluorescein isothiocyanate (FITC). Antibodies against Brucella in animal sera prevented the binding of the donor-labeled MAb to the acceptor-labeled antigen, thus inhibiting the TR-FRET signal formation. The authors examined 480 infected and 73 uninfected ruminants' samples and reported their (competitive) assay to have 100% diagnostic sensitivity and specificity. We set up a related TR-FRET-based, homogeneous assay for human serodiagnosis, with PUUV-caused HFRS as the first clinical application. We at first examined the suitability of two MAbs, 1C12 and 3H9, with distinct epitope specificities and antigen binding affinities. We observed better FRET inhibition with MAb 3H9 than with MAb 1C12. Therefore, MAb 3H9 was selected as the competing antibody for the assay. Notably, 3H9 binds to a variable loop at aa 251 to 260 of N and is specific to PUUV, whereas the largely cross-reactive 1C12 avidly detects most of the pathogenic rodent-borne hantaviruses (even the distant Hantaan and Seoul viruses). In essence, we think that while specific, 3H9 is a weaker binder than 1C12 and consequently easier to compete with. Also, our current data suggest that the 3H9 epitope indeed is recognized by the antibodies of most if not all patients with acute NE, whereas with the previous use of pin-bound peptides, human antibody binding to linear peptides representing the 3H9 epitope region could be demonstrated in only 9/16 PUUV-seropositive individuals (27) . There are likely conformational aspects of this epitope that allow all seropositives to react with this epitope in the properly folded recombinant protein, although the MAb itself is also reactive with the respective linear peptide.
We studied two separate sample sets: a retrospective panel (panel 1; n ϭ 128) and a prospective panel (panel 2; n ϭ 201). Altogether, 329 samples were studied, and the results were comparable (Table 3) . Acute-phase PUUV infection was identified with 99.1% specificity and 100% sensitivity. The sensitivity among past-infection samples was 78.5% (with 99.7% specificity), albeit with assay parameters optimized for IgM detection. This sensitivity could possibly be increased via optimization for IgG detection. On the other hand, to account for our observation that only in cases of acute NE did all individuals produce antibodies competing with the MAb 3H9 epitope binding, we cannot exclude the possibility that there is more interindividual variation in epitope recognition in past-infection sera than in the acute-phase IgMs. This could likely be overcome by using another MAb or a mixture of MAbs.
We conducted experiments to compare the sensitivities of the CFRET-IA and the reference methods. The CFRET-IA showed lower sensitivity for detecting both IgG and IgM than the reference tests. Whereas very little correlation was seen for either IgM a Results of sample panels 1 and 2 (n ϭ 329) using CFRET-IA were combined and compared to results of the reference methods. The samples from the two panels comprised 101 acute-phase (acute), 42 past-infection (past), and 186 seronegative samples. The threshold for positivity in CFRET-IA was set at Ͼ20% relative TR-FRET inhibition.
or IgG titers with those obtained using the CFRET-IA test, we further summed up the IgM and IgG-IFA titers and observed a significant correlation (0.62) with the CFRET-IA results, possibly reflecting the property of this test to detect both antibody classes. Additionally, we compared the performances of CFRET-IA and the previously described TR-FRET-based assay LFRET (18) by analyzing 124 (60 acute-infection, 26 past-infection, and 45 seronegative) samples. Although CFRET-IA was somewhat more sensitive than LFRET in the diagnosis of acute PUUV infection (100% versus 95%), none of the seronegatives gave a positive reaction with either assay. Compared to CFRET-IA, in which the antigen and antibody are applied at nonsaturating concentrations, the LFRET assay is more robust in setup, with merely protein L supplied at a saturating concentration. In addition, CFRET-IA in this setting only detects antibodies to a single epitope. To conclude, the herein described CFRET-IA identified acute PUUV infection with excellent sensitivity and specificity in an assay time of 30 min. We believe this assay format to be widely applicable to a number of other human pathogens, requiring merely a labeled antigen and a suitable MAb targeting a conserved epitope as previously shown for veterinary diagnostics. Also, being a one-step assay, this new tool could qualify for screening of viral antibodies among animal species lacking commercial secondary antibodies. In addition to acute-phase diagnostics, the assay did recognize samples with long-term immunity, albeit with lower sensitivity. Further development is warranted toward such a comprehensive serodiagnostic concept.
